These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 38676368)

  • 1. Prospects of focal adhesion kinase inhibitors as a cancer therapy in preclinical and early phase study.
    Gao J; Cheng J; Xie W; Zhang P; Liu X; Wang Z; Zhang B
    Expert Opin Investig Drugs; 2024 Jun; 33(6):639-651. PubMed ID: 38676368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FAK inhibitors in Cancer, a patent review.
    Lv PC; Jiang AQ; Zhang WM; Zhu HL
    Expert Opin Ther Pat; 2018 Feb; 28(2):139-145. PubMed ID: 29210300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FAK-targeted and combination therapies for the treatment of cancer: an overview of phase I and II clinical trials.
    Mohanty A; Pharaon RR; Nam A; Salgia S; Kulkarni P; Massarelli E
    Expert Opin Investig Drugs; 2020 Apr; 29(4):399-409. PubMed ID: 32178538
    [No Abstract]   [Full Text] [Related]  

  • 4. Drug Discovery Targeting Focal Adhesion Kinase (FAK) as a Promising Cancer Therapy.
    Pang XJ; Liu XJ; Liu Y; Liu WB; Li YR; Yu GX; Tian XY; Zhang YB; Song J; Jin CY; Zhang SY
    Molecules; 2021 Jul; 26(14):. PubMed ID: 34299525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FAK inhibitors in cancer, a patent review - an update on progress.
    Ye YX; Cao YY; Xu LS; Wang HC; Liu XH; Zhu HL
    Expert Opin Ther Pat; 2024 Aug; 34(8):593-610. PubMed ID: 38946486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic Receptor Tyrosine Kinases Directly Phosphorylate Focal Adhesion Kinase (FAK) as a Resistance Mechanism to FAK-Kinase Inhibitors.
    Marlowe TA; Lenzo FL; Figel SA; Grapes AT; Cance WG
    Mol Cancer Ther; 2016 Dec; 15(12):3028-3039. PubMed ID: 27638858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Focal adhesion kinase inhibitors in the treatment of metastatic cancer: a patent review.
    Shanthi E; Krishna MH; Arunesh GM; Venkateswara Reddy K; Sooriya Kumar J; Viswanadhan VN
    Expert Opin Ther Pat; 2014 Oct; 24(10):1077-100. PubMed ID: 25113248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging roles of focal adhesion kinase in cancer.
    Tai YL; Chen LC; Shen TL
    Biomed Res Int; 2015; 2015():690690. PubMed ID: 25918719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting focal adhesion kinase signaling in tumor growth and metastasis.
    Schwock J; Dhani N; Hedley DW
    Expert Opin Ther Targets; 2010 Jan; 14(1):77-94. PubMed ID: 20001212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting focal adhesion kinase (FAK) for cancer therapy: FAK inhibitors, FAK-based dual-target inhibitors and PROTAC degraders.
    Yang M; Xiang H; Luo G
    Biochem Pharmacol; 2024 Jun; 224():116246. PubMed ID: 38685282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting focal adhesion kinase (FAK) in cancer therapy: A recent update on inhibitors and PROTAC degraders.
    Wang X; Li N; Liu YH; Wu J; Liu QG; Niu JB; Xu Y; Huang CZ; Zhang SY; Song J
    Eur J Med Chem; 2024 Oct; 276():116678. PubMed ID: 39029337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting FAK in anticancer combination therapies.
    Dawson JC; Serrels A; Stupack DG; Schlaepfer DD; Frame MC
    Nat Rev Cancer; 2021 May; 21(5):313-324. PubMed ID: 33731845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Focal adhesion kinase-An emerging viable target in cancer and development of focal adhesion kinase inhibitors.
    Chauhan A; Khan T
    Chem Biol Drug Des; 2021 Mar; 97(3):774-794. PubMed ID: 33191630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting focal adhesion kinase in cancer cells and the tumor microenvironment.
    Murphy JM; Rodriguez YAR; Jeong K; Ahn EE; Lim SS
    Exp Mol Med; 2020 Jun; 52(6):877-886. PubMed ID: 32514188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Focal adhesion kinase signaling - tumor vulnerabilities and clinical opportunities.
    Schlaepfer DD; Ojalill M; Stupack DG
    J Cell Sci; 2024 Jul; 137(14):. PubMed ID: 39034922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer.
    Schultze A; Fiedler W
    Expert Opin Investig Drugs; 2010 Jun; 19(6):777-88. PubMed ID: 20465362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Focal adhesion kinase as a cancer therapy target.
    Golubovskaya VM
    Anticancer Agents Med Chem; 2010 Dec; 10(10):735-41. PubMed ID: 21214510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Roles and inhibitors of FAK in cancer: current advances and future directions.
    Hu HH; Wang SQ; Shang HL; Lv HF; Chen BB; Gao SG; Chen XB
    Front Pharmacol; 2024; 15():1274209. PubMed ID: 38410129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment.
    Stokes JB; Adair SJ; Slack-Davis JK; Walters DM; Tilghman RW; Hershey ED; Lowrey B; Thomas KS; Bouton AH; Hwang RF; Stelow EB; Parsons JT; Bauer TW
    Mol Cancer Ther; 2011 Nov; 10(11):2135-45. PubMed ID: 21903606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress in the Development of Small Molecular Inhibitors of Focal Adhesion Kinase (FAK).
    Lu Y; Sun H
    J Med Chem; 2020 Dec; 63(23):14382-14403. PubMed ID: 33058670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.